BT
BioGene Therapeutics Inc.
SEC filingBiotechnology · Austin, TX
Amount raised$3Msold at filing
Total offering$3M
Investors in the raise1count reported to the SEC
FiledAug 7, 2026first sale Jun 5, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
STEVE GLOVERDirector
DAVID TYRONNE HOWTONDirector
STEPHEN VAN DEVENTERExecutive Officer, Director
RAJ PRUTHIDirector
PATROSKI LAWSONDirector
DEEPAK SAMPATHDirector
Executive officers, directors and promoters as listed on the Form D.